Franklin Genomic Advancements ETF (HELX)

Assets	$23.02M
Expense Ratio	0.50%
PE Ratio	29.40
Shares Out	650,000
Dividend (ttm)	$0.14
Dividend Yield	0.42%
Ex-Dividend Date	Dec 30, 2025
Payout Frequency	n/a
Payout Ratio	11.90%

Volume	520
Open	34.18
Previous Close	35.05
Day's Range	34.16 - 34.45
52-Week Low	26.06
52-Week High	38.17
Beta	1.00
Holdings	64
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

44.82% of assets

Name	Symbol	Weight
Guardant Health, Inc.	GH	8.91%
Natera, Inc.	NTRA	6.85%
Krystal Biotech, Inc.	KRYS	5.78%
United Therapeutics Corporation	UTHR	4.02%
Ligand Pharmaceuticals Incorporated	LGND	3.83%
BridgeBio Pharma, Inc.	BBIO	3.50%
Adaptive Biotechnologies Corporation	ADPT	3.23%
Eli Lilly and Company	LLY	3.04%
AstraZeneca PLC	AZN	2.92%
Vertex Pharmaceuticals Incorporated	VRTX	2.76%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 30, 2025	$0.14334	Jan 8, 2026
Dec 30, 2021	$0.00394	Jan 7, 2022
Dec 13, 2021	$0.11415	Dec 21, 2021
Dec 14, 2020	$0.05178	Dec 23, 2020

Performance

HELX had a total return of 33.03% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.93%.